A US FDA advisory committee’s overwhelming endorsement of the efficacy and safety of GlaxoSmithKline PLC’s Krintafel (tafenoquine) for prevention of malaria relapse positions the company to nab a tropical disease priority review voucher by the application’s July 22 user fee deadline.
On July 12, the Antimicrobial Drugs Advisory Committee voted 13-0 that GSK provided substantial evidence tafenoquine is effective for the...





